Abstract: Disclosed herein are methods of administering resiniferatoxin (RTX) perineurally for treatment of maladaptive pain, and compositions for use in such methods.

Abstract: A delivery system is described that includes a controlled release device that includes a crosslinked poly(glycerol sebacate) (PGS) or other glycerol ester and a controlled release compound, the controlled release device being provided in a contracted state and being expandable to a three-dimensional expanded state in a target location. The delivery systems provides an expandible, flexible biodegradable elastomer loaded with an active ingredient to allow for extended release for different dosage forms for either human or animal health products in vivo, delivered through the gastrointestinal tract.

Abstract: Compositions include highly concentrated Alpha-1 Proteinase Inhibitor (A1PI) in a concentration greater than or equal to 100 mg/ml. Pharmaceutical compositions can be prepared from these compositions. The pharmaceutical compositions can be suitable for subcutaneous administration. The highly concentrated A1PI solutions can be obtained by single-pass tangential flow filtration (SPTFF).

Abstract: The present disclosure relates to compositions and methods for the treatment of topical skin conditions. Also provided are topically applied compositions and delivery systems. Also provided are methods of using the compositions and delivery systems in cosmetic, personal care and dermatology applications. Also provided is a sprayable composition that comprises petrolatum.

Abstract: A nanonization method for cannabidiol (CBD) includes following steps: the CBD is dissolved in a good solvent to obtain a CBD-good solvent solution, the CBD-good solvent solution is added to aqueous solution of a stabilizer to obtain mixed solution, the mixed solution is ultrasonicated followed by removing the good solvent by rotary evaporation from the mixed solution to obtain a nanosized CBD suspension. The stabilizer includes one or more selected from the group consisting of poloxamer, tween, polyoxyethylene alkyl ether, polyvinyl pyrrolidone, hydroxypropyl methyl cellulose and carboxymethyl chitosan. Particle size of the CBD is reduced in the nanonization method for the CBD through the nanonization of insoluble drugs to obtain the nanosized CBD suspension. In the nanosized CBD suspension, nanosized CBD has high solid content. The nanonization method for the CBD achieves solubilization of the CBD.

Abstract: The present disclosure relates to, inter alia, a formulation in a package, the formulation comprises one or more active agents and is co-mingled with a whipping agent prior to being filled under pressure into the package. The whipping agent is added in sufficient amounts to be dispersed in the formulation. The pressurized package is under sufficient pressure suitable to maintain the whipping agent dispersed in the formulation; and the pressurized package is under sufficient pressure to expel the formulation as a whipped formulation upon application of external force on the formulation in the package.

Abstract: The present invention relates to a method for producing an andrographolide carrier system, comprising: (i) preparing a dispersed phase by dissolving andrographolide in ethanol solvent; (ii) preparing an inner encapsulating carrier layer; (iii) forming a protective encapsulating layer of the active agent; (iv) forming bonds to attach mucoadhesion enhancers onto the surface structure of the encapsulating layer, and then bringing the mixture to room temperature, slowly adding hydroxypropyl methylcellulose HPMC; (v) heating until the temperature reaches 50° C., adding Polysorbate 80 and PEG-40 hydrogenated castor oil to the mixture, with further stirring under vacuum; and (vi) filtering the product by injection through a nanofilter system.

Abstract: The objective of the present invention is to provide a capsule filling composition which can stably produce a capsule formulation by suppressing the flow of components out of the capsule body during capsule filling, regardless of the compressibility of an active ingredient such as drugs and health foods, so that a favorable capsule filling can be achieved; and a method of producing a capsule formulation with the use of such a capsule filling composition, as well as a capsule formulation. The objective is achieved by a method of producing a capsule formulation, comprising subjecting a capsule filling composition containing an active ingredient and a cellulose ether powder to a funnel system powder filling or a die-compression system powder filling to obtain the capsule formulation, and the like.

Abstract: The invention relates to solid formulations (especially water-dispersible granules) of tetramic acid derivatives and mixtures of these tetramic acid derivatives, to a process for production thereof and to the use thereof for application of the active ingredients present.

Abstract: According to the invention there is provided a method of improving (e.g. restoring) function in a patient having idiopathic pulmonary fibrosis, which method comprises perorally administering a therapeutically-effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof, to said patient. Said treatment is capable of treating said IPF in a therapeutic, including a curative, fashion.

Abstract: Disclosed herein are exemplary medical devices for controlled delivery of material compositions, particularly occlusive, therapeutic, or diagnostic compositions.

Abstract: The present invention discloses compositions and methods for repair and reconstruction of defects and injuries to soft tissues. Some aspects of the disclosure provide methods for corneal reconstruction by applying an engineered bioadhesive, glycidyl methacrylate-substituted gelatin and a visible light activated photoinitiator in presence of visible light to the corneal defect.

Abstract: The present disclosure relates to compositions and methods for the treatment of topical skin conditions. Also provided are topically applied compositions and delivery systems. Also provided are methods of using the compositions and delivery systems in cosmetic, personal care and dermatology applications. Also provided is a sprayable composition that comprises petrolatum.

Abstract: Aspects of the disclosure relate methods and synthetic scaffolds for regenerating hollow tubular organs present in the respiratory system such as bronchus tissue.

Abstract: The present invention relates to a pharmaceutical composition stabilized in a gelled state at at least a temperature varying from 15° C. to 40° C., comprising at least one aqueous phase gelled with at least one hydrophilic polymeric gelling agent, lipid nanocapsules comprising a liquid or semi-liquid lipid core at room temperature enveloped in a lipid envelope which is solid at room temperature, said gelled aqueous phase and nanocapsules containing at least one antibiotic, identical or different, the antibiotic in said aqueous phase being present there in the form of a solute.

Abstract: The invention provides a dosage form and a bolus configured for administration to an animal, wherein said dosage form and said bolus is configured to release a methane inhibitor to the animal over a period of time. Preferably the methane inhibitor is a haloform. Also provided is the use of the bolus of the invention to reduce methane production in a ruminant animal. Also provided is the method of manufacturing a bolus of the invention.

Abstract: Compositions and methods for improving gastrointestinal function and reducing the presence of gas bubbles in a gastrointestinal tract. A composition includes an effective amount of ginger root extract for reducing gas bubbles in a gastrointestinal tract and further includes propylene glycol and sodium chloride.

Abstract: The invention provides particles, compositions including the particles, and methods of making the particles using electrospray. In certain embodiments, the particles allow for high concentrations of a therapeutic or diagnostic agent to be delivered at low viscosity. Particles may also exhibit beneficial properties with respect to stability.

Abstract: Storage stable sterile ready-to-administer formulations comprising N-acetylcysteine are presented with desirable stability characteristics. In preferred aspects, formulations comprise low quantities of one or more chelating agents, contain N-acetylcysteine at a concentration of 25 mg/mL or 50 mg/mL, and are packaged in a suitable format, such as a polymeric bag with a metalized overwrap and a non-contact oxygen scavenger.

Abstract: The present disclosure relates to compositions, methods of use and methods of manufacturing of transdermal delivery systems, patches, vehicles and devices including an iontophoretic transdermal delivery system, patch, vehicle or device used to relieve pain (i.e., analgesics) and/or inflammation that contain a pharmaceutically effective amount of a pharmaceutically acceptable and effective cannabinoid and menthol.